Latest Olaparib Stories
WALTHAM, Mass., Feb.
Ovarian and breast cancer treatments being developed that mix a protein inhibitor and traditional anticancer drugs are showing signs of success, according to a new review for Faculty of 1000 Biology Reports.
Breast cancer patients who have triple negative breast cancer, an aggressive form of the disease, that has spread to other parts of the body, are being asked to participate in a clinical study of a promising new treatment called PARP inhibitors.
New findings may help explain why women who carry a mutated BRCA1 gene have greater rates of infertility as well as a greater risk for breast and ovarian cancer.
WALTHAM, Mass., Nov.
The ultimate goal in cancer research, a treatment that kills cancer cells whilst leaving healthy cells untouched, is brought nearer by the success of a new therapeutic approach.
Women with mutations in either their BRCA1 or BRCA2 genes have a dramatically increased risk of developing breast or ovarian cancer.
Men who develop prostate cancer face an increased risk of having an aggressive tumor if they carry a so-called breast cancer gene mutation, scientists from the Albert Einstein College of Medicine of Yeshiva University report in today's issue of Clinical Cancer Research. The findings could help to guide prostate-cancer patients and their physicians in choosing treatment options.
BRISBANE, Calif., April 10 /PRNewswire/ -- BiPar Sciences, Inc. today announced the expansion of the clinical program for the company's lead product candidate, BSI-201, into glioblastoma multiforme (GBM), the most common glioma in adults.
NEW YORK (Reuters Health) - Women with BRCA1 gene mutations, which confer a high risk of developing breast cancer, might decrease their risk by drinking a lot of coffee, according to a multicenter team of investigators. Dr. Steven A.
- The act of sweetening by admixture of some saccharine substance.